About OnyvaxSciencePress ReleasesClinical TrialsCareersContact
Onyvax - oncology vaccines 

Company Profile







About Onyvax image

Company Profile

Onyvax is developing new cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells. Onyvax's products specifically target cancer cells, increasing the likelihood that they will be effective while minimising side effects associated with many conventional treatments. These therapies can broadly be classed as therapeutic cancer vaccines.

Onyvax's lead product is in clinical trials for the treatment of prostate cancer and is poised to enter the final stages of development. Onyvax is committed to the commercialisation of novel therapies that enhance survival while maintaining a high quality of life for patients. The Company is based in London and has collaborations with leading hospitals and other institutions throughout Europe and the US.

 

 

 

 

 


© 1998-2009 Onyvax Ltd. All Rights Reserved